Updated data from the phase II NADIM trials indicate that combining neoadjuvant nivolumab with chemotherapy benefits patients with operable non–small cell lung cancer, boosting rates of pathologic complete response as well as progression-free and overall survival. RNA sequencing may also have uncovered biomarkers that could better pinpoint patients at high risk of disease progression despite treatment.

You do not currently have access to this content.